Literature DB >> 8372632

Clinical and demographic features of HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Rio de Janeiro, Brazil.

A de Q Araújo1, C R Alfonso, D Schor, A C Leite, M J de Andrada-Serpa.   

Abstract

In Rio de Janeiro (RJ) most cases of paraparesis of obscure origin are associated with the human T-cell lymphotropic virus type I (HTLV-I). Thirty-four consecutive patients with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) from RJ were evaluated. Most patients came from low socio-economic levels. There was no difference in terms of gender. The main affected racial group was white. A history of sexually transmitted diseases was a major risk factor for HAM/TSP and a positive serology for syphilis was found in 26.5% of the patients. The major clinical findings were of a spastic paraparesis with generalized brisk tendon jerks and bilateral Babinki's sign. Sensation was abnormal in 25 patients (73.5%) and five (14.7%) had a sensory level. Three patients (8.8%) had optic atrophy. The cerebrospinal fluid showed a lymphocytic pleocytosis with a mean total protein content of 0.4 g/litre, and an increased intrathecal IgG synthesis in 59.4% of patients. HAM/TSP and multiple sclerosis (MS) occur indigenously in RJ and some HAM/TSP cases can be sometimes confused with MS. Therefore we propose that, in places where MS coexist with HAM/TSP, HTLV-I antibodies should be sought routinely in those MS suspected cases with prominent spastic paraparesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8372632     DOI: 10.1111/j.1600-0404.1993.tb04188.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  9 in total

Review 1.  HTLV-1 and HIV infections of the central nervous system in tropical areas.

Authors:  P Cabre; D Smadja; A Cabié; C R Newton
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-05       Impact factor: 10.154

Review 2.  Tropical spastic paraparesis/HTLV-I associated myelopathy. Etiology and clinical spectrum.

Authors:  P E Rodgers-Johnson
Journal:  Mol Neurobiol       Date:  1994 Apr-Jun       Impact factor: 5.590

3.  HTLV: It Is Time to Reach a Consensus on Its Nomenclature.

Authors:  Antonio Carlos Rosário Vallinoto; Carolina Rosadas; Luiz Fernando Almeida Machado; Graham P Taylor; Ricardo Ishak
Journal:  Front Microbiol       Date:  2022-04-22       Impact factor: 6.064

4.  Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis.

Authors:  Yoshihisa Yamano; Tomoo Sato
Journal:  Front Microbiol       Date:  2012-11-09       Impact factor: 5.640

5.  Recurrent Spontaneous Rupture of the Urinary Bladder in a Patient With Human T-lymphotropic Virus Type 1-Associated Myelopathy: A Case Report and Literature Review.

Authors:  Behzad Feizzadeh Kerigh; Reza Boostani; Alireza Ghoreifi
Journal:  Nephrourol Mon       Date:  2014-02-02

6.  Clinical and laboratory features of HTLV-I asymptomatic carriers and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis from the Brazilian Amazon.

Authors:  Massanobu Takatani; Myuki Esashika Crispim; Nelson Fraiji; Mariane Martins Araujo Stefani; Dagmar Kiesslich
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-04-03       Impact factor: 1.846

Review 7.  The challenge of describing the epidemiology of HTLV in the Amazon region of Brazil.

Authors:  Ricardo Ishak; Marluísa de Oliveira Guimarães Ishak; Antonio Carlos R Vallinoto
Journal:  Retrovirology       Date:  2020-02-14       Impact factor: 4.602

8.  Bladder dysfunction in human T cell lymphotropic virus infection: A prospective cohort study.

Authors:  José Abraão Carneiro Neto; Cássius José Vitor de Oliveira; Sheila Nunes Ferraz; Mariele Guerra; Lívia Alves Oliveira; Lúcia Passos; Edgar M Carvalho; Paulo Novis Rocha
Journal:  PLoS Negl Trop Dis       Date:  2022-01-14

9.  Barefoot Plantar Pressure Indicates Progressive Neurological Damage in Patients with Human T-Cell Lymphotropic Virus Type 1 Infection.

Authors:  Beatriz Helena B Vasconcelos; Givago S Souza; Tatiana G C P Barroso; Luiz Carlos L Silveira; Rita Catarina M Sousa; Bianca Callegari; Marília B Xavier
Journal:  PLoS One       Date:  2016-03-21       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.